Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Chf Medical and Innovation Ofr | March 03, 2026 | March 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date March 03, 2026 · Filed March 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 273,602 |
Reported balance
After 2026-03-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-03 · Grant · Acquired 50,125 · Balance 273,602 F1: Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 267,190 |
Reported balance
After 2026-03-04 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-03-04 · Sale · Disposed 6,412 · Balance 267,190 F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3: This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.30 · Expires 2036-03-03 | Direct | 73,340 |
Reported balance
After 2026-03-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-03-03 · Grant · Acquired 73,340 · Balance 73,340 F4: Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates.
F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F3: This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price.
F4: Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2026 Filed Mar 5, 2026 16:32 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 6,412 | $13.31 | $85,314.22 |
DisclosureSEC source: 0001811030-26-000003 · primarydocument.xml · nonDerivative · entry 2 Weinberg Uri · CIK 0001811030 · Chf Medical and Innovation Ofr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 267,190 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 16:32 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Option (Right to Buy) · Derivative | 73,340 | $0.00 Strike: $13.30 | $0.00 |
DisclosureSEC source: 0001811030-26-000003 · primarydocument.xml · derivative · entry 3 Weinberg Uri · CIK 0001811030 · Chf Medical and Innovation Ofr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,340 Underlying: Ordinary Shares · 73,340 shares Expires 2036-03-03 F4 · derivative.exercise_date: Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 16:32 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 50,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001811030-26-000003 · primarydocument.xml · nonDerivative · entry 1 Weinberg Uri · CIK 0001811030 · Chf Medical and Innovation Ofr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 273,602 F1 · security: Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 16:11 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 3,272 | $13.33 | $43,606.93 |
DisclosureSEC source: 0001811030-26-000002 · primarydocument.xml · nonDerivative · entry 3 Weinberg Uri · CIK 0001811030 · Chf Medical and Innovation Ofr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,477 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $13.31 USD to $13.36 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| February 28, 2026 Filed Mar 3, 2026 16:11 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 12,992 | $0.00 | $0.00 |
DisclosureSEC source: 0001811030-26-000002 · primarydocument.xml · nonDerivative · entry 2 Weinberg Uri · CIK 0001811030 · Chf Medical and Innovation Ofr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,749 F3 · security: Represents vesting of performance-based restricted stock units. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 16:11 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 7,461 | $13.84 | $103,256.51 |
DisclosureSEC source: 0001811030-26-000002 · primarydocument.xml · nonDerivative · entry 1 Weinberg Uri · CIK 0001811030 · Chf Medical and Innovation Ofr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,757 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.79 USD to $13.91 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 16:41 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Options (Right to buy) · Derivative | 81,499 | $18.19 Strike: $18.19 | $1,482,466.81 |
DisclosureSEC source: 0001562180-25-002160 · primarydocument.xml · derivative · entry 2 Weinberg Uri · CIK 0001811030 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,499 Underlying: Ordinary Shares · 81,499 shares Expires 2035-03-03 F2 · derivative.exercise_date: Options to buy 81,499 ordinary shares will vest in equal installments on each of March 4, 2026, 2027, 2028 and 2029, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 16:41 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 54,975 | $18.19 | $999,995.25 |
DisclosureSEC source: 0001562180-25-002160 · primarydocument.xml · nonDerivative · entry 1 Weinberg Uri · CIK 0001811030 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,218 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on March 4, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 16:19 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 268 | $18.92 | $5,071.02 |
DisclosureSEC source: 0001562180-25-001977 · primarydocument.xml · nonDerivative · entry 1 Weinberg Uri · CIK 0001811030 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,243 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: On the transaction date, the reporting person sold 268 shares in multiple trades at prices ranging from $18.8304 to $18.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:27 UTC Amendment | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 311 | $18.31 | $5,695.28 |
DisclosureSEC source: 0001562180-25-001917 · primarydocument.xml · nonDerivative · entry 2 Weinberg Uri · CIK 0001811030 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,511 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: On February 28, 2025, the reporting person sold 311 shares in multiple trades at prices ranging from $18.30 to $18.316. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:27 UTC Amendment | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,326 | $18.78 | $81,253.96 |
DisclosureSEC source: 0001562180-25-001917 · primarydocument.xml · nonDerivative · entry 1 Weinberg Uri · CIK 0001811030 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,822 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: On February 28, 2025, the reporting person sold 4,326 shares in multiple trades at prices ranging from $18.73 to $18.86. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 16:28 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 311 | $18.31 | $5,695.28 |
DisclosureSEC source: 0001562180-25-001837 · primarydocument.xml · nonDerivative · entry 2 Weinberg Uri · CIK 0001811030 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,511 F2 · price: On February 28, 2025, the reporting person sold 311 shares in multiple trades at prices ranging from $18.30 to $18.316. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 16:28 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,326 | $18.78 | $81,253.96 |
DisclosureSEC source: 0001562180-25-001837 · primarydocument.xml · nonDerivative · entry 1 Weinberg Uri · CIK 0001811030 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,822 F1 · price: On February 27, 2025, the reporting person sold 4,326 shares in multiple trades at prices ranging from $18.73 to $18.86. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 16:35 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Options (Right to buy) · Derivative | 125,078 | $16.30 Strike: $16.30 | $2,038,771.40 |
DisclosureSEC source: 0001562180-24-001986 · primarydocument.xml · derivative · entry 2 Weinberg Uri · CIK 0001811030 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,078 Underlying: Ordinary Shares · 125,078 shares Expires 2034-02-26 F2 · derivative.exercise_date: Options to buy 125,078 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 16:35 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 81,799 | $16.30 | $1,333,323.70 |
DisclosureSEC source: 0001562180-24-001986 · primarydocument.xml · nonDerivative · entry 1 Weinberg Uri · CIK 0001811030 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,148 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. Read SEC document |
| June 30, 2023 Filed Jul 6, 2023 16:15 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 305 | $35.28 | $10,760.40 |
DisclosureSEC source: 0001562180-23-005762 · primarydocument.xml · nonDerivative · entry 1 Weinberg Uri · CIK 0001811030 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,349 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January1, 2023 through June 30, 2023. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2023. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 16:43 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 3,936 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-002494 · primarydocument.xml · nonDerivative · entry 2 Weinberg Uri · CIK 0001811030 · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,044 F1 · shares: Represents vesting of performance-based restricted stock units. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 16:43 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 28,830 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-002494 · primarydocument.xml · nonDerivative · entry 1 Weinberg Uri · CIK 0001811030 · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,108 F1 · shares: Represents vesting of performance-based restricted stock units. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 16:58 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 21,607 | $76.97 Strike: $76.97 | $1,663,090.79 |
DisclosureSEC source: 0001645113-23-000029 · wf-form4_167779429653064.xml · derivative · entry 2 Weinberg Uri · CIK 0001811030 · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,607 Underlying: Ordinary Shares · 21,607 shares Expires 2033-02-27 F2 · derivative.exercise_date: Options to buy 21,607 ordinary shares will vest and become exercisable in equal installments on each of February 28, 2024, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 16:58 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 12,992 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-23-000029 · wf-form4_167779429653064.xml · nonDerivative · entry 1 Weinberg Uri · CIK 0001811030 · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,278 F1 · shares: Represents restricted share units that are scheduled to vest on February 28, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 18:24 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 1,946 | $0.00 Strike: $47.04 | $0.00 |
DisclosureSEC source: 0001645113-23-000010 · wf-form4_167330663055285.xml · derivative · entry 6 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,946 Underlying: Ordinary Shares · 1,946 shares Expires 2029-03-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Weinberg. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 18:24 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,201 | $120.00 | $144,120.00 |
DisclosureSEC source: 0001645113-23-000010 · wf-form4_167330663055285.xml · nonDerivative · entry 5 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,286 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Weinberg. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 18:24 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,617 | $108.00 | $282,636.00 |
DisclosureSEC source: 0001645113-23-000010 · wf-form4_167330663055285.xml · nonDerivative · entry 4 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,487 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Weinberg. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 18:24 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,946 | $120.00 | $233,520.00 |
DisclosureSEC source: 0001645113-23-000010 · wf-form4_167330663055285.xml · nonDerivative · entry 3 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,104 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Weinberg. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 18:24 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 1,946 | $47.04 | $91,539.84 |
DisclosureSEC source: 0001645113-23-000010 · wf-form4_167330663055285.xml · nonDerivative · entry 2 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Weinberg. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 18:24 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,379 | $120.00 | $285,480.00 |
DisclosureSEC source: 0001645113-23-000010 · wf-form4_167330663055285.xml · nonDerivative · entry 1 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,104 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Weinberg. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 17:51 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 281 | $59.08 | $16,600.08 |
DisclosureSEC source: 0001645113-22-000066 · wf-form4_165723064834354.xml · nonDerivative · entry 1 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,483 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2022 through June 30, 2022. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2022. F3 · balance_after: Amended total to correct prior mathematical error. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 18:25 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 4,961 | $80.59 Strike: $80.59 | $399,806.99 |
DisclosureSEC source: 0001645113-22-000021 · wf-form4_164669550591279.xml · derivative · entry 3 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,961 Underlying: Ordinary Shares · 4,961 shares Expires 2032-02-29 F3 · shares: Options to buy 4,961 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 18:25 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 30,422 | $80.59 Strike: $80.59 | $2,451,708.98 |
DisclosureSEC source: 0001645113-22-000021 · wf-form4_164669550591279.xml · derivative · entry 2 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,422 Underlying: Ordinary Shares · 30,422 shares Expires 2032-02-29 F2 · shares: Options to buy 30,422 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 18:25 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 17,371 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-22-000021 · wf-form4_164669550591279.xml · nonDerivative · entry 1 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,186 F1 · shares: Represents restricted share units that are scheduled to vest on March 1, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates. Read SEC document |
| January 06, 2022 Filed Jan 12, 2022 17:41 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 35 | $63.82 | $2,233.63 |
DisclosureSEC source: 0001645113-22-000008 · wf-form4_164202724976066.xml · nonDerivative · entry 1 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,815 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2021 through December 31, 2021. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on December 31, 2021. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 17:38 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 113 | $137.12 | $15,494.79 |
DisclosureSEC source: 0001645113-21-000089 · wf-form4_162578028082781.xml · nonDerivative · entry 1 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,780 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2021 through June 30, 2021. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2021. Read SEC document |
| May 10, 2021 Filed May 12, 2021 16:13 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 3,846 | $0.00 Strike: $47.56 | $0.00 |
DisclosureSEC source: 0001645113-21-000066 · wf-form4_162085040881642.xml · derivative · entry 4 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,845 Underlying: Ordinary Shares · 3,846 shares Expires 2029-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| May 10, 2021 Filed May 12, 2021 16:13 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,804 | $189.65 | $342,128.60 |
DisclosureSEC source: 0001645113-21-000066 · wf-form4_162085040881642.xml · nonDerivative · entry 3 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,667 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Weinberg. Read SEC document |
| May 10, 2021 Filed May 12, 2021 16:13 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 3,846 | $189.65 | $729,393.90 |
DisclosureSEC source: 0001645113-21-000066 · wf-form4_162085040881642.xml · nonDerivative · entry 2 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,471 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Weinberg. Read SEC document |
| May 10, 2021 Filed May 12, 2021 16:13 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 3,846 | $47.56 | $182,915.76 |
DisclosureSEC source: 0001645113-21-000066 · wf-form4_162085040881642.xml · nonDerivative · entry 1 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,317 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 16:40 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 3,892 | $0.00 Strike: $47.04 | $0.00 |
DisclosureSEC source: 0001645113-21-000048 · wf-form4_161670479191751.xml · derivative · entry 3 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,892 Underlying: Ordinary Shares · 3,892 shares Expires 2029-03-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 16:40 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 3,892 | $140.00 | $544,880.00 |
DisclosureSEC source: 0001645113-21-000048 · wf-form4_161670479191751.xml · nonDerivative · entry 2 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,306 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Weinberg. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 16:40 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 3,892 | $47.04 | $183,079.68 |
DisclosureSEC source: 0001645113-21-000048 · wf-form4_161670479191751.xml · nonDerivative · entry 1 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,198 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 23, 2021 Filed Apr 9, 2021 16:25 UTC Amendment | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,835 | $140.00 | $396,900.00 |
DisclosureSEC source: 0001645113-21-000051 · wf-form4a_161799991891111.xml · nonDerivative · entry 1 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,471 F1 · security: Amending original form 4 filed on March 25, 2021 to add additional transaction inadvertently omitted. F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Weinberg. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 17:54 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 16,003 | $0.00 Strike: $153.09 | $0.00 |
DisclosureSEC source: 0001645113-21-000032 · wf-form4_161489844997400.xml · derivative · entry 2 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,003 Underlying: Ordinary Shares · 16,003 shares Expires 2031-03-01 F2 · derivative.exercise_date: Options to buy 16,003 ordinary shares will vest and become exercisable in equal installments on each of March 2, 2022, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 17:54 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Share Units | 8,709 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-21-000032 · wf-form4_161489844997400.xml · nonDerivative · entry 1 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,306 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on each of March 2, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 16:16 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 6,500 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001645113-21-000015 · wf-form4_161420137542064.xml · derivative · entry 3 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,500 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 16:16 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 6,500 | $175.50 | $1,140,750.00 |
DisclosureSEC source: 0001645113-21-000015 · wf-form4_161420137542064.xml · nonDerivative · entry 2 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,597 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Weinberg. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 16:16 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 6,500 | $7.15 | $46,475.00 |
DisclosureSEC source: 0001645113-21-000015 · wf-form4_161420137542064.xml · nonDerivative · entry 1 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,097 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 18:13 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 6,500 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001645113-20-000141 · wf-form4_160133119236559.xml · derivative · entry 6 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Ordinary Shares · 6,500 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 18:13 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 8,750 | $0.00 Strike: $11.46 | $0.00 |
DisclosureSEC source: 0001645113-20-000141 · wf-form4_160133119236559.xml · derivative · entry 5 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,750 shares Expires 2026-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 18:13 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 6,500 | $103.35 | $671,775.00 |
DisclosureSEC source: 0001645113-20-000141 · wf-form4_160133119236559.xml · nonDerivative · entry 4 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,597 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Weinberg. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 18:13 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 6,500 | $7.15 | $46,475.00 |
DisclosureSEC source: 0001645113-20-000141 · wf-form4_160133119236559.xml · nonDerivative · entry 3 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,097 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 18:13 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 8,750 | $103.35 | $904,312.50 |
DisclosureSEC source: 0001645113-20-000141 · wf-form4_160133119236559.xml · nonDerivative · entry 2 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,597 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Weinberg. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.